Current topics in hepatitis B

Journal of Infection

Volumn 41, Issue 2, 2000, Pages 130-136

  Zuckerman, J N ^a   Zuckerman, A J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMINO ACID; ANTIVIRUS AGENT; ENTECAVIR; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS ANTIGEN; VIRUS DNA; VIRUS RNA;

ANTIBODY RESPONSE; BLOOD DONOR; CHRONICITY; CONTROLLED STUDY; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; INCIDENCE; KINETICS; LABORATORY TEST; LIVER DISEASE; LIVER TRANSPLANTATION; MORTALITY; REVIEW; SCREENING; VIRUS CARRIER; VIRUS MUTATION;

EID: 0033760560     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2000.0720     Document Type: Article

References (44)

1. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production
2. Are booster immunizations needed for lifelong hepatitis B immunity?
3. Immune response to hepatitis B revaccination
4. Half-life of HBs antibody after hepatitis B vaccination: An aid to timing of booster vaccination
5. In vitro anti-HBs production by individual B cells of responders to hepatitis B vaccine who subsequently lost antibody
6. Hepatitis B vaccination: Non-responders must be detected
7. Immunogenicity of a novel triple-S hepatitis B vaccine in nonresponder health care workers
8. Immunization against hepatitis B - What can we expect?
9. Molecular epidemiology of hepatitis B virus mutants
10. Natural history of hepatitis B surface antigen mutants in children
11. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan
12. Incidence and significance of hepatitis B core antibody in a healthy blood donor population
13. Significance of isolated hepatitis B core antibodies detected in a high risk population
14. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection. Implications in hepatitis B vaccination programs
15. Significance of isolated anti-HBc seropositivity by ELISA: Implications and the role of radioimmunoassay
16. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine
17. The serological pattern of ″anti-HBc alone″. Report on a Workshop
18. Complete genomes, phylogenetic relatedness and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes
19. Molecular variants of hepatitis B virus
20. Hepatitis B variant in Europe
21. Vaccine-induced escape mutant of hepatitis B virus
22. The effect of hepatitis B virus mutants on efficacy of vaccination
23. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore
24. Hepatitis B virus (HBV) antibody resistant mutants among mothers and infants with chronic HBV infection
25. Mutations of some critical amino acid residues in the hepatitis B surface antigen
26. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia
27. Immunoassay detection of hepatitis B surface antigen mutants
28. Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring ″a″ loop escape mutations
29. Effect of variation in the common ″a″ determinant on the antigenicity of hepatitis B surface antigen
30. High genetic variability of the group specific a-determinant of hepatitis B surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum
31. The predicted pattern of emergence of vaccine-resistant hepatitis B: A cause for concern?
32. Predictions of the emergence of vaccine-resistant hepatitis B in the Gambia using a mathematical model
33. Interferon therapy of chronic hepatitis B
34. The treatment of chronic viral hepatitis
35. Profound suppression of hepatitis B virus replication with lamivudine
36. Hepatitis B e antigen seroconversion: Effects of lamivudine alone or in combination with interferon alpha
37. Liver disease - Significant improvement with lamivudine
38. Lamivudine for hepatitis B in clinical practice
39. Management of hepatitis B in China
40. Response of pre-core mutant chronic hepatitis B infection to lamivudine
41. End-stage liver disease and liver transplantation: Role of lamivudine therapy in patients with chronic hepatitis B
42. Treatment options for chronic hepatitis. Antivirals look promising